Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Aug;12(15):1273-1285.
doi: 10.2217/epi-2019-0335. Epub 2020 Sep 1.

Methylation of immune-regulatory cytokine genes and pancreatic cancer outcomes

Brian Z Huang  1   2   3 , Alexandra M Binder  1   4 , Catherine A Sugar  5   6 , Chun R Chao  2 , Veronica Wendy Setiawan  3   7 , Zuo-Feng Zhang  1
Affiliations

Methylation of immune-regulatory cytokine genes and pancreatic cancer outcomes

Brian Z Huang et al. Epigenomics. 2020 Aug.

Abstract

Aim: Given the immunosuppressive nature of pancreatic cancer, we investigated the relationship between epigenetic modification of immune-regulatory cytokine genes and pancreatic cancer outcomes. Materials & methods: We evaluated DNA methylation of 184 pancreatic tumor samples from The Cancer Genome Atlas for 111 CpG loci in seven cytokine genes: IL10, IL6, IL8, TGFβ1, TGFβ2, TGFβ3 and TNF. We used Cox regression to evaluate the associations between methylation and overall survival, disease-specific survival and disease progression (α = 0.05). Results: Poorer survival was associated with increased methylation in fifteen CpG probes in TGFβ1, TGFβ2, TGFβ3 and TNF. We also detected improved outcomes for three loci in IL10, IL8 and IL6. Conclusion: Epigenetic regulation of cytokine-related gene expression may be associated with pancreatic cancer outcomes.

Keywords: cytokines; epigenetics; immune system; methylation; pancreatic cancer; progression; survival.

PubMed Disclaimer

Conflict of interest statement

Financial & competing interests disclosure

Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health (K07CA225856 to AM Binder, T32CA009142 to ZF Zhang). BZ Huang is supported by T32 Training Grants from the NCI/NIH (T32CA009142, T32CA229110; https://www.cancer.gov/). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. C. A. Cancer J. Clin. 70(1), 7–30 (2020). - PubMed
    1. Ryan DP, Hong TS, Bardeesy N. Pancreatic adenocarcinoma. N. Engl. J. Med. 371(22), 2140–2141 (2014). - PubMed
    1. Sideras K, Braat H, Kwekkeboom J. et al. Role of the immune system in pancreatic cancer progression and immune modulating treatment strategies. Cancer Treat. Rev. 40(4), 513–522 (2014). - PubMed
    1. Evans A, Costello E. The role of inflammatory cells in fostering pancreatic cancer cell growth and invasion. Front. Physiol. 3, 270 (2012). - PMC - PubMed
    1. Chang JH, Jiang Y, Pillarisetty VG. Role of immune cells in pancreatic cancer from bench to clinical application: an updated review. Medicine (Baltimore). 95(49), e5541 (2016). - PMC - PubMed

Publication types